IMR Press / RCM / Volume 6 / Issue S4 / pii/1561344112234-109175572

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Upper GI Risks of NSAIDs and Antiplatelet Agents: Key Issues for the Cardiologist
Show Less
1 Division of Gastroenterology, Eastern Virginia Medical School, Norfolk, VA
Rev. Cardiovasc. Med. 2005, 6(S4), 15–22;
Published: 20 August 2005
The use of antiplatelet/antithrombotic agents (eg, low-dose aspirin or clopidogrel) in primary or secondary intervention treatment strategies for cardiovascular disease is a common practice among cardiologists. Furthermore, these agents frequently are used concomitantly with other nonsteroidal anti-inflammatory drugs (NSAIDs) that patients are taking for a wide array of rheumatologic- or orthopedic-related complaints. These therapies, however, have defined upper gastrointestinal (UGI) risks for ulcer-related injury and complications. It is important for the cardiologist to fully understand the UGI risk profiles so that each patient is evaluated as a candidate for possible preventive co-therapy with appropriate anti-ulcer medication.
Upper gastrointestinal bleeding
Peptic ulcer
Low-dose aspirin
Antithrombotic agents
Antiplatelet agents
Helicobacter pylori
Back to top